Lamotrigine

Drug Profile

Lamotrigine

Alternative Names: 430C78; BW 430C; Labileno; Lamactil; Lamictal; Lamictin

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Antiepileptic drugs; Small molecules; Triazines
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bipolar disorders; Lennox-Gastaut syndrome; Partial epilepsies; Tonic-clonic epilepsy
  • Phase III Absence epilepsy; Epilepsy
  • Discontinued Diabetic neuropathies; Neuropathic pain; Schizophrenia

Most Recent Events

  • 14 Jun 2016 Biomarkers information updated
  • 01 Nov 2015 GlaxoSmithKline completes a phase III trial in Absence epilepsy (In adolescents, In children, Monotherapy, Newly diagnosed) in Japan and South Korea (NCT01431976)
  • 08 May 2015 Phase-III development for Absence epilepsy is ongoing in Japan and South Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top